Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $28.38, for a total transaction of $14,190.00. Following the completion of the transaction, the director now directly owns 73,909 shares of the company's stock, valued at $2,097,537.42. This represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amphastar Pharmaceuticals Stock Down 1.7 %
Shares of NASDAQ:AMPH opened at $27.80 on Thursday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of 9.27, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The firm's 50 day moving average price is $30.62 and its 200 day moving average price is $39.55.
Wall Street Analyst Weigh In
Separately, Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st.
Read Our Latest Stock Analysis on Amphastar Pharmaceuticals
Institutional Investors Weigh In On Amphastar Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets raised its stake in Amphastar Pharmaceuticals by 59.6% in the third quarter. BNP Paribas Financial Markets now owns 94,466 shares of the company's stock valued at $4,584,000 after buying an additional 35,284 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after acquiring an additional 398 shares in the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $10,804,000. Portolan Capital Management LLC boosted its holdings in Amphastar Pharmaceuticals by 201.1% in the third quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock valued at $15,906,000 after purchasing an additional 218,901 shares in the last quarter. Finally, Point72 DIFC Ltd boosted its holdings in Amphastar Pharmaceuticals by 85.9% in the third quarter. Point72 DIFC Ltd now owns 3,954 shares of the company's stock valued at $192,000 after purchasing an additional 1,827 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
